Skip to main content
Erschienen in: Journal of Nephrology 2/2021

01.04.2021 | Original Article

Increased circulating Cathepsin-K levels reflect PTH control in chronic hemodialysis patients

verfasst von: Davide Bolignano, Marta Greco, Valentina Arcidiacono, Omar Tripolino, Caterina Vita, Michele Provenzano, Cinzia Donato, Salvatore Chiarella, Giorgio Fuiano, Giovambattista De Sarro, Emilio Russo, Michele Andreucci, Daniela Patrizia Foti, Giuseppe Coppolino

Erschienen in: Journal of Nephrology | Ausgabe 2/2021

Einloggen, um Zugang zu erhalten

Abstract

Background

Mineral bone disease (MBD) is remarkably frequent among chronic hemodialysis (HD) patients. In this setting, deranged PTH levels portend an adjunctive risk of worsen outcomes. Various evidence exists demonstrating that PTH strongly induces Cathepsin-K, a cysteine protease mainly found in lysosomes of osteoclasts and macrophages which promotes bone and extracellular matrix remodelling. Cathepsin-K levels are altered in various bone disorders, systemic inflammation and even in non-advanced CKD. In this study, we tested the hypothesis of an association between Cathepsin-K, uremic-MBD and circulating PTH levels in a cohort of chronic HD patients.

Methods

We measured Cathepsin-K in 85 stable chronic HD patients and dialysis vintage > 6 months by a commercially available ELISA kit and we collected routine clinical parameters, including intact PTH. Patients were further stratified according to their “on- target” or “off-target” PTH status.

Results

Cathepsin-K levels were significantly higher in HD patients than in healthy controls (p < 0.0001) and were independently associated with alkaline phosphatase (β = 0.37; p < 0.001), PTH (β = 0.30; p = 0.02) and C-reactive protein (β = 0.24; p = 0.008) levels. Cathepsin-K was also higher in patients with off-target PTH as compared to those with controlled PTH levels (230 [40–420] vs. 3250 [820–4205] pg/mL; p < 0.0001). At ROC analyses, Cathepsin-K levels were able to identify off-target PTH and parathyroidectomized patients (AUCs 0.85 [95% CI 0.71–0.98] and 0.97 [95% CI 0.92–0.99], respectively).

Conclusion

In chronic HD patients, Cathepsin-K associates with PTH levels, raising the intriguing hypothesis that this protein represents a causal link between mineral and inflammatory complications and could be tested as a candidate biomarker of MBD severity and PTH balance.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
1.
Zurück zum Zitat Collaboration GBDCKD (2020) Global, regional, and national burden of chronic kidney disease, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet 395(10225):709–733CrossRef Collaboration GBDCKD (2020) Global, regional, and national burden of chronic kidney disease, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet 395(10225):709–733CrossRef
2.
Zurück zum Zitat Provenzano M, Coppolino G, De Nicola L et al (2019) Unraveling cardiovascular risk in renal patients: a new take on old tale. Front Cell Dev Biol 7:314CrossRef Provenzano M, Coppolino G, De Nicola L et al (2019) Unraveling cardiovascular risk in renal patients: a new take on old tale. Front Cell Dev Biol 7:314CrossRef
3.
Zurück zum Zitat Provenzano M, Coppolino G, Faga T et al (2019) Epidemiology of cardiovascular risk in chronic kidney disease patients: the real silent killer. Rev Cardiovasc Med 20(4):209–220CrossRef Provenzano M, Coppolino G, Faga T et al (2019) Epidemiology of cardiovascular risk in chronic kidney disease patients: the real silent killer. Rev Cardiovasc Med 20(4):209–220CrossRef
4.
Zurück zum Zitat Lunyera J, Scialla JJ (2018) Update on chronic kidney disease mineral and bone disorder in cardiovascular disease. Semin Nephrol 38(6):542–558CrossRef Lunyera J, Scialla JJ (2018) Update on chronic kidney disease mineral and bone disorder in cardiovascular disease. Semin Nephrol 38(6):542–558CrossRef
5.
Zurück zum Zitat Kazama JJ, Wakasugi M (2018) Parathyroid hormone and bone in dialysis patients. Ther Apher Dial 22(3):229–235CrossRef Kazama JJ, Wakasugi M (2018) Parathyroid hormone and bone in dialysis patients. Ther Apher Dial 22(3):229–235CrossRef
6.
Zurück zum Zitat Coppolino G, Bolignano D, De Paola L et al (2011) Parathyroid hormone and mobilization of circulating bone marrow-derived cells in uremic patients. J Investig Med 59(5):823–828CrossRef Coppolino G, Bolignano D, De Paola L et al (2011) Parathyroid hormone and mobilization of circulating bone marrow-derived cells in uremic patients. J Investig Med 59(5):823–828CrossRef
7.
Zurück zum Zitat De Paola L, Coppolino G, Bolignano D et al (2010) Parathyroid hormone variability parameters for identifying high turnover osteodystrophy disease in hemodialysis patients: an observational retrospective cohort study. Ther Apher Dial 14(6):566–571CrossRef De Paola L, Coppolino G, Bolignano D et al (2010) Parathyroid hormone variability parameters for identifying high turnover osteodystrophy disease in hemodialysis patients: an observational retrospective cohort study. Ther Apher Dial 14(6):566–571CrossRef
9.
Zurück zum Zitat Vizovisek M, Fonovic M, Turk B (2019) Cysteine Cathepsins in extracellular matrix remodeling: extracellular matrix degradation and beyond. Matrix Biol 75–76:141–159CrossRef Vizovisek M, Fonovic M, Turk B (2019) Cysteine Cathepsins in extracellular matrix remodeling: extracellular matrix degradation and beyond. Matrix Biol 75–76:141–159CrossRef
10.
Zurück zum Zitat Troen BR (2004) The role of Cathepsin K in normal bone resorption. Drug News Perspect 17(1):19–28CrossRef Troen BR (2004) The role of Cathepsin K in normal bone resorption. Drug News Perspect 17(1):19–28CrossRef
11.
Zurück zum Zitat Liu CL, Guo J, Zhang X et al (2018) Cysteine protease Cathepsins in cardiovascular disease: from basic research to clinical trials. Nat Rev Cardiol 15(6):351–370CrossRef Liu CL, Guo J, Zhang X et al (2018) Cysteine protease Cathepsins in cardiovascular disease: from basic research to clinical trials. Nat Rev Cardiol 15(6):351–370CrossRef
12.
Zurück zum Zitat Zhao Q, Jia Y, Xiao Y (2009) Cathepsin K: a therapeutic target for bone diseases. Biochem Biophys Res Commun 380(4):721–723CrossRef Zhao Q, Jia Y, Xiao Y (2009) Cathepsin K: a therapeutic target for bone diseases. Biochem Biophys Res Commun 380(4):721–723CrossRef
13.
Zurück zum Zitat Izumi Y, Hayashi M, Morimoto R et al (2016) Impact of circulating Cathepsin K on the coronary calcification and the clinical outcome in chronic kidney disease patients. Heart Vessels 31(1):6–14CrossRef Izumi Y, Hayashi M, Morimoto R et al (2016) Impact of circulating Cathepsin K on the coronary calcification and the clinical outcome in chronic kidney disease patients. Heart Vessels 31(1):6–14CrossRef
14.
Zurück zum Zitat Kidney Disease: Improving Global Outcomes CKDMBDUWG (2017) KDIGO 2017 clinical practice guideline update for the diagnosis, evaluation, prevention, and treatment of Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD). Kidney Int Suppl (2011) 7(1):1–59CrossRef Kidney Disease: Improving Global Outcomes CKDMBDUWG (2017) KDIGO 2017 clinical practice guideline update for the diagnosis, evaluation, prevention, and treatment of Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD). Kidney Int Suppl (2011) 7(1):1–59CrossRef
15.
Zurück zum Zitat Vidak E, Javorsek U, Vizovisek M et al (2019) Cysteine Cathepsins and their extracellular roles: shaping the microenvironment. Cells 8(3):264CrossRef Vidak E, Javorsek U, Vizovisek M et al (2019) Cysteine Cathepsins and their extracellular roles: shaping the microenvironment. Cells 8(3):264CrossRef
16.
Zurück zum Zitat Chapurlat RD, Confavreux CB (2016) Novel biological markers of bone: from bone metabolism to bone physiology. Rheumatol (Oxf) 55(10):1714–1725CrossRef Chapurlat RD, Confavreux CB (2016) Novel biological markers of bone: from bone metabolism to bone physiology. Rheumatol (Oxf) 55(10):1714–1725CrossRef
17.
Zurück zum Zitat Drake MT, Clarke BL, Oursler MJ et al (2017) Cathepsin K inhibitors for osteoporosis: biology, potential clinical utility, and lessons learned. Endocr Rev 38(4):325–350CrossRef Drake MT, Clarke BL, Oursler MJ et al (2017) Cathepsin K inhibitors for osteoporosis: biology, potential clinical utility, and lessons learned. Endocr Rev 38(4):325–350CrossRef
18.
Zurück zum Zitat Conaghan PG, Bowes MA, Kingsbury SR et al (2020) Disease-modifying effects of a novel Cathepsin K inhibitor in osteoarthritis: a randomized, placebo-controlled study. Ann Intern Med 172(2):86–95CrossRef Conaghan PG, Bowes MA, Kingsbury SR et al (2020) Disease-modifying effects of a novel Cathepsin K inhibitor in osteoarthritis: a randomized, placebo-controlled study. Ann Intern Med 172(2):86–95CrossRef
19.
Zurück zum Zitat Li W, Yuan L, Tong G et al (2018) Phospholipase C signaling activated by parathyroid hormone mediates the rapid osteoclastogenesis in the fracture healing of orchiectomized mice. BMC Musculoskelet Disord 19(1):311CrossRef Li W, Yuan L, Tong G et al (2018) Phospholipase C signaling activated by parathyroid hormone mediates the rapid osteoclastogenesis in the fracture healing of orchiectomized mice. BMC Musculoskelet Disord 19(1):311CrossRef
20.
Zurück zum Zitat Khan MP, Singh AK, Singh AK et al (2018) Odanacatib restores trabecular bone of skeletally mature female rabbits with osteopenia but induces brittleness of cortical bone: a comparative study of the investigational drug with PTH, estrogen, and alendronate. J Bone Miner Res 33(11):2084–2085CrossRef Khan MP, Singh AK, Singh AK et al (2018) Odanacatib restores trabecular bone of skeletally mature female rabbits with osteopenia but induces brittleness of cortical bone: a comparative study of the investigational drug with PTH, estrogen, and alendronate. J Bone Miner Res 33(11):2084–2085CrossRef
21.
Zurück zum Zitat Carrillo-Lopez N, Panizo S, Alonso-Montes C et al (2016) Direct inhibition of osteoblastic Wnt pathway by fibroblast growth factor 23 contributes to bone loss in chronic kidney disease. Kidney Int 90(1):77–89CrossRef Carrillo-Lopez N, Panizo S, Alonso-Montes C et al (2016) Direct inhibition of osteoblastic Wnt pathway by fibroblast growth factor 23 contributes to bone loss in chronic kidney disease. Kidney Int 90(1):77–89CrossRef
22.
Zurück zum Zitat Friedrichs B, Tepel C, Reinheckel T et al (2003) Thyroid functions of mouse Cathepsins B, K, and L. J Clin Invest 111(11):1733–1745CrossRef Friedrichs B, Tepel C, Reinheckel T et al (2003) Thyroid functions of mouse Cathepsins B, K, and L. J Clin Invest 111(11):1733–1745CrossRef
23.
Zurück zum Zitat Vizovisek M, Vidak E, Javorsek U et al (2020) Cysteine Cathepsins as therapeutic targets in inflammatory diseases. Expert Opin Ther Targets 24(6):573–588CrossRef Vizovisek M, Vidak E, Javorsek U et al (2020) Cysteine Cathepsins as therapeutic targets in inflammatory diseases. Expert Opin Ther Targets 24(6):573–588CrossRef
24.
Zurück zum Zitat Sandro M, Martini N, Silverio R et al (2020) Bone, inflammation and chronic kidney disease. Clin Chim Acta 506:236–240CrossRef Sandro M, Martini N, Silverio R et al (2020) Bone, inflammation and chronic kidney disease. Clin Chim Acta 506:236–240CrossRef
25.
Zurück zum Zitat Coppolino G, Lucisano G, Rivoli L et al (2015) Serum beta-crosslaps as predictor of long-term parathyroid hormone levels in hemodialysis patients. J Investig Med 63(3):539–544CrossRef Coppolino G, Lucisano G, Rivoli L et al (2015) Serum beta-crosslaps as predictor of long-term parathyroid hormone levels in hemodialysis patients. J Investig Med 63(3):539–544CrossRef
26.
Zurück zum Zitat Fusaro M, Gallieni M, Aghi A et al (2019) Osteocalcin (bone GLA protein) levels, vascular calcifications, vertebral fractures and mortality in hemodialysis patients with diabetes mellitus. J Nephrol 32(4):635–643CrossRef Fusaro M, Gallieni M, Aghi A et al (2019) Osteocalcin (bone GLA protein) levels, vascular calcifications, vertebral fractures and mortality in hemodialysis patients with diabetes mellitus. J Nephrol 32(4):635–643CrossRef
27.
Zurück zum Zitat Suassuna PGA, de Paula RB, Sanders-Pinheiro H et al (2019) Fibroblast growth factor 21 in chronic kidney disease. J Nephrol 32(3):365–377CrossRef Suassuna PGA, de Paula RB, Sanders-Pinheiro H et al (2019) Fibroblast growth factor 21 in chronic kidney disease. J Nephrol 32(3):365–377CrossRef
Metadaten
Titel
Increased circulating Cathepsin-K levels reflect PTH control in chronic hemodialysis patients
verfasst von
Davide Bolignano
Marta Greco
Valentina Arcidiacono
Omar Tripolino
Caterina Vita
Michele Provenzano
Cinzia Donato
Salvatore Chiarella
Giorgio Fuiano
Giovambattista De Sarro
Emilio Russo
Michele Andreucci
Daniela Patrizia Foti
Giuseppe Coppolino
Publikationsdatum
01.04.2021
Verlag
Springer International Publishing
Erschienen in
Journal of Nephrology / Ausgabe 2/2021
Print ISSN: 1121-8428
Elektronische ISSN: 1724-6059
DOI
https://doi.org/10.1007/s40620-020-00801-5

Weitere Artikel der Ausgabe 2/2021

Journal of Nephrology 2/2021 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Bei seelischem Stress sind Checkpoint-Hemmer weniger wirksam

03.06.2024 NSCLC Nachrichten

Wie stark Menschen mit fortgeschrittenem NSCLC von einer Therapie mit Immun-Checkpoint-Hemmern profitieren, hängt offenbar auch davon ab, wie sehr die Diagnose ihre psychische Verfassung erschüttert

Erhebliches Risiko für Kehlkopfkrebs bei mäßiger Dysplasie

29.05.2024 Larynxkarzinom Nachrichten

Fast ein Viertel der Personen mit mäßig dysplastischen Stimmlippenläsionen entwickelt einen Kehlkopftumor. Solche Personen benötigen daher eine besonders enge ärztliche Überwachung.

Nach Herzinfarkt mit Typ-1-Diabetes schlechtere Karten als mit Typ 2?

29.05.2024 Herzinfarkt Nachrichten

Bei Menschen mit Typ-2-Diabetes sind die Chancen, einen Myokardinfarkt zu überleben, in den letzten 15 Jahren deutlich gestiegen – nicht jedoch bei Betroffenen mit Typ 1.

15% bedauern gewählte Blasenkrebs-Therapie

29.05.2024 Urothelkarzinom Nachrichten

Ob Patienten und Patientinnen mit neu diagnostiziertem Blasenkrebs ein Jahr später Bedauern über die Therapieentscheidung empfinden, wird einer Studie aus England zufolge von der Radikalität und dem Erfolg des Eingriffs beeinflusst.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.